Elysium Health, a company developing health products from ageing research, plans to offer six additional peptides through Elysium Health Rx by the end of 2026. Peptides are short chains of amino acids, the building blocks of proteins. The company’s November 5 announcement makes availability conditional on applicable regulations and an individual physician’s evaluation. PR Newswire (source, opens in new tab)
PR NewswireElysium Health™ Expands Access to Six Additional Peptides Under New HHS Policy and Announces Launch of Peptide Research ProgramsOpen source (opens in new tab) Elysium Health (source, opens in new tab)
Elysium HealthAbout Our Company & MissionOpen source (opens in new tab)
The plans follow an interim policy from the US Department of Health and Human Services (HHS) on compounding: preparing or altering a drug for an individual patient’s needs. HHS says it does not intend to take enforcement action against specified pharmacies, federal facilities and licensed physicians using these peptides, provided they meet its conditions. U.S. Department of Health and Human Services (source, opens in new tab)U.S. Department of Health and Human ServicesHHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug SubstancesOpen source (opens in new tab)
This approach, known as enforcement discretion, is not approval by the US Food and Drug Administration (FDA). Compounded drugs are not FDA-approved, and the policy does not establish that these peptides are safe or effective. Elysium itself acknowledges that human clinical evidence is limited.
The six peptides are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The policy requires patient-specific prescriptions and sets conditions covering the identity of the peptides, how they are administered, their manufacturers and product characteristics, and the reporting of adverse events.
The arrangement is temporary. It applies while the list of bulk drug substances permitted under the US 503A compounding framework is developed through formal rulemaking. HHS may revisit the policy as that process continues.
Elysium also announced two research initiatives. PEER is intended to give qualified research institutions access to peptides with defined characteristics through what the company describes as a controlled, traceable supply chain. This is a plan to supply research materials, rather than a report of research results.
The proposed TIME-PEP study would examine epigenetic patterns—chemical marks involved in regulating gene activity—associated with peptide use. It would explore possible relationships with biological-age measures, which estimate aspects of biological ageing, and with illness and death. The announcement provides no study protocol, participant numbers or results, leaving open how those relationships would be tested.
- PR Newswire · Company releaseElysium Health™ Expands Access to Six Additional Peptides Under New HHS Policy and Announces Launch of Peptide Research Programsprnewswire.com · opens in new tab
- U.S. Department of Health and Human Services · Regulatory recordHHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substanceshhs.gov · opens in new tab
